British startup Potential Sciences has secured backing from the UK Government’s Sovereign AI venture fund as part of an eight-figure fundraising round announced. The investment, alongside access to computing resources, will support the company’s development of artificial intelligence (AI) technology for chemical design and drug discovery.
Potential Sciences is developing an AI model based on the fundamental laws of physics rather than relying primarily on historical experimental data. The approach aims to address a key bottleneck in AI-driven chemical and pharmaceutical research: the dependence on data generated through expensive and time-consuming laboratory experiments.
According to the company, its technology could make the AI calculations required to design chemicals up to 100 times cheaper than current approaches. This could help researchers explore a wider range of chemical compounds and potential drug candidates, including those targeting diseases for which research has been constrained by high development costs.
AI-based chemical design is opening new possibilities for pharmaceutical research, including the development of potential treatments for conditions such as cancer and Parkinson’s disease. However, conventional AI approaches often depend on extensive experimental datasets, limiting the scope and economics of certain research programmes.
By focusing on the underlying physics of chemical systems, Potential Sciences aims to reduce this dependence on experimental data and make computational chemical discovery more accessible. The company’s approach could potentially expand research into diseases and therapeutic areas that have historically received limited attention because of the costs involved.
The Sovereign AI venture fund is a UK Government initiative designed to support promising early-stage AI companies through investment and access to resources required to develop and scale their technologies. The backing for Potential Sciences reflects the government's focus on strengthening domestic AI capabilities and supporting innovation in strategically important sectors.
AI Minister Kanishka Narayan said the company was drawing on the UK's strengths in data, fundamental science and computing to advance medical discovery. He added that addressing chemistry's data bottleneck could enable researchers to investigate treatments for diseases that are currently considered too rare or expensive to study.
The investment and computing support are expected to help Potential Sciences advance its AI research and contribute to the development of technologies that could accelerate chemical innovation and future drug discovery.
